Human parainfluenza viruses (HPIVs) commonly cause upper and lower respiratory illnesses in infants and young children. But, anyone can get respiratory illness from HPIV.
Symptoms of upper respiratory illness may include fever, runny nose, and cough. HPIVs can cause more severe lower respiratory illness, such as croup or pneumonia. Young children are more likely to have these severe illnesses. But, older adults and people with weakened immune systems are also at risk.
You can have multiple HPIV illnesses in your lifetime.
HPIVs spread from person to person through close personal contact, in the air by coughing and sneezing, and by touching objects or surfaces that have HPIVs on them.
Vaccine virus was recovered from Vero cells using plasmid rescue procedure and was further expanded in Vero cells as previously described by Tang et al. AccuSpray sprayers were filled with a 0.2 mL single intranasal dose of MEDI-534 containing 10^4, 10^5, or 10^6 median tissue culture infectious dose (Gomez et al., 2009)
h. Immunization Route
intranasal immunization
i . Approved Age for Licensed Use
1 to 9 year old children
j. Description
MEDI-534 is a live, attenuated, intranasal vaccine against RSV and PIV3. It is a chimeric bovine/human (b/h) PIV3 construct that expresses the hPIV3 fusion (F), the hPIV3 hemagglutinin-neuraminidase, and the RSV F proteins from a bPIV3 viral genome. (Gomez et al., 2009)
2. mRNA-1653
a. Type:
mRNA vaccine
b. Status:
Licensed
c. Host Species for Licensed Use:
Human
d. Antigen
The sources of the encoded antigens were the hMPV A strain, TN/92-4, and the PIV3 strain, PER/FLA4815/2008. (August et al., 2022)
The mRNA-1653 vaccine is bivalent, containing 2 distinct nucleoside-modified mRNA sequences encoding the native, membrane-anchored fusion glycoproteins of hMPV and PIV3 encapsulated in a lipid nanoparticle.(August et al., 2022)
3. rHPIV1 84/del170/942A
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species for Licensed Use:
None
d. Preparation
One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry (Makula et al., 1978)
e. Immunization Route
intranasal immunization
f. Description
rHPIV1 84/del170/942A Is a live attenuated human parainfluenza type 1 virus vaccine administered intranasally via nose drops.(Makula et al., 1978)
4. rHPIV3cp45 Vaccine
a. Manufacturer:
Charles River Laboratories
b. Type:
Live recombinant vaccine
c. Status:
Licensed
d. Host Species for Licensed Use:
Baboon
e. Preparation
Vaccine virus was stored frozen at −70 °C and had a mean infectivity titer of 107 tissue culture infectious doses (TCID50) per mL. Final vial content was diluted to dose on-site. (Englund et al., 2013)
2. Kobayashi et al., 2013: Kobayashi H, Iwatsuki-Horimoto K, Kiso M, Uraki R, Ichiko Y, Takimoto T, Kawaoka Y. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine. Vaccine. 2013; 31(52); 6239-6246. [PubMed: 24144478].
